Enoblituzumab (Anti-B7-H3 / CD276)
Enoblituzumab (Anti-B7-H3 / CD276) is a humanized IgG1κ monoclonal antibody targeting human B7-H3 protein. It can be used in the treatment of medullary thyroid cancer (MTC). MW :150 KD.
Supplier | Selleck Chemicals |
---|---|
Product # | A2626 |
Sku # | A2626-1mg |
Pricing | 1mg, $370.00 |